Previously Untreated Activated B-Cell (ABC) Type Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard Chemotherapy compared to Combination Chemothearpy (ROBUST)

Purpose

To evaluate the efficacy & safety of standard chemotherapy versus combination chemotherapy in patients who have previously untreated ABC type DLBCL.

Criteria

Must be between the ages of 18-80 years old

Histologically confirmed DLBCL Measurable disease on CT imaging

Adequate liver, renal, cardiac, & bone marrow function

No prior treatment for DLBCL No HBV, HCV, or HIV

Details

Screening: All assessments must be completed within 28 days prior to Cycle1 Day 1. Patients will undergo safety & other assessments to determine eligibility for the study. Once eligibility is confirmed, the patient will be randomized to which treatment they will receive.

Treatment: Begins with Cycle 1 Day 1 dosing of the randomized chemotherapy drugs. Patients may receive up to 6 cycles of treatment

Follow-Up: Begins upon treatment discontinuation. Patients will be followed until progression.

Interested in more information? Contact Us:

Michael Moore, M.D., Principal Investigator
Hematology Oncology Associates
(318) 212-8620

IRB: Willis-Knighton
IRB Number: 15.0007
Trial Type: Drug
Sponsor: Celgene Corporation